Novanta Inc (1GSN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novanta Inc (1GSN) has a cash flow conversion efficiency ratio of 0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€8.49 Million ≈ $9.93 Million USD) by net assets (€801.48 Million ≈ $937.01 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Novanta Inc (1GSN) defensive interval to measure how many days the company can operate on defensive assets alone.
Novanta Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Novanta Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novanta Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novanta Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR
|
0.014x |
|
KONINKLIJKE VOP.UNSP.ADR
F:VPK
|
N/A |
|
Cousins Properties Incorporated
NYSE:CUZ
|
0.009x |
|
GEPIC Energy Development Co Ltd
SHE:000791
|
0.102x |
|
ExlService Holdings Inc
NASDAQ:EXLS
|
0.002x |
|
Clear Secure Inc
NYSE:YOU
|
-0.285x |
|
Sai MicroElectronics Inc
SHE:300456
|
-0.006x |
|
IPG Photonics Corporation
NASDAQ:IPGP
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Novanta Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Novanta Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 1GSN company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €745.70 Million ≈ $871.80 Million |
€158.51 Million ≈ $185.32 Million |
0.213x | +19.22% |
| 2023-12-31 | €673.46 Million ≈ $787.35 Million |
€120.08 Million ≈ $140.38 Million |
0.178x | +13.44% |
| 2022-12-31 | €577.59 Million ≈ $675.26 Million |
€90.78 Million ≈ $106.13 Million |
0.157x | -13.41% |
| 2021-12-31 | €521.29 Million ≈ $609.44 Million |
€94.62 Million ≈ $110.63 Million |
0.182x | -38.28% |
| 2020-12-31 | €476.81 Million ≈ $557.44 Million |
€140.24 Million ≈ $163.95 Million |
0.294x | +94.00% |
| 2019-12-31 | €417.17 Million ≈ $487.72 Million |
€63.25 Million ≈ $73.94 Million |
0.152x | -37.72% |
| 2018-12-31 | €368.25 Million ≈ $430.53 Million |
€89.65 Million ≈ $104.81 Million |
0.243x | +19.67% |
| 2017-12-31 | €311.55 Million ≈ $364.23 Million |
€63.38 Million ≈ $74.10 Million |
0.203x | +10.20% |
| 2016-12-31 | €258.87 Million ≈ $302.65 Million |
€47.79 Million ≈ $55.87 Million |
0.185x | +35.18% |
| 2015-12-31 | €244.70 Million ≈ $286.08 Million |
€33.42 Million ≈ $39.07 Million |
0.137x | -- |
About Novanta Inc
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. It operates in two segments, Automation Enabling Technologies and Medical Solutions. The Precision Medicine and Manufacturing segment designs, manufactures, and markets las… Read more